We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
QSI Gears Up to Post Q2 Earnings: What's in Store for the Stock?
Read MoreHide Full Article
Key Takeaways
{\"0\":\"QuantumSi set to report Q2 2025 results on Aug. 5, with revenues projected at $1.52 million.\",\"1\":\"Growth is driven by international expansion, Platinum Pro adoption, and new sequencing kits.\",\"2\":\"U.S. academic market softness and NIH funding uncertainty weigh on new instrument purchases.\"}
The Zacks Consensus Estimate for second-quarter revenues is pegged at $1.52 million, suggesting growth of 145.2% from the year-ago quarter’s reported figure.
The consensus mark for loss is pegged at 16 cents per share, unchanged over the past 60 days. QSI reported a loss of 16 cents per share in the year-ago quarter.
QSI’s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters, while matching the same on one occasion, with the average surprise being 18.35%.
Let’s see how things have shaped up prior to this announcement.
QSI's first-quarter performance is expected to have benefited from rapid traction for its offerings at a global level. At the end of the first quarter of 2025, QSI had 23 international distribution partners, with 60% of instruments installed outside the United States.
QuantumSi is poised for a potential rise in pharma and government adoption of its products. Stability in Pharma and biotech R&D and continuing adoption of the Platinum Pro system are likely to boost QSI’s top line in the second quarter.
QuantumSi is on track to release Version 4 Sequencing Kit and Version 3 of Library Preparation Kit to expand applications, leading to more growth scopes. Proteus platform on track for prototype sequencing in 2025 and commercial launch in H2 2026, promising higher throughput and broader proteomics coverage.
QuantumSi has also been engaging with the scientific community, presenting research at major industry conferences, including the Human Proteome Organization World Congress and the American Society of Human Genetics Conference. QuantumSi’s efforts raise awareness and credibility for its Platinum platform, potentially leading to greater customer adoption.
However, QSI is experiencing a slowdown in new instrument purchases due to NIH funding uncertainty and the U.S. Academic market weakness.
What Our Proven Model Says for QSI’s Q2 Earnings
Our proven model does not conclusively predict an earnings beat for QSI this time. According to the Zacks model, the combination of a positive Earnings ESP and Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here.
QSI has an Earnings ESP of 0.00% and carries a Zacks Rank #3 at present. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks With Favorable Combination
Here are some companies worth considering, as our model shows that these have the right combination of elements to beat earnings in their upcoming releases:
Image: Shutterstock
QSI Gears Up to Post Q2 Earnings: What's in Store for the Stock?
Key Takeaways
QuantumSi Incorporated (QSI - Free Report) is scheduled to report its second-quarter 2025 results on Aug. 5, 2025.
The Zacks Consensus Estimate for second-quarter revenues is pegged at $1.52 million, suggesting growth of 145.2% from the year-ago quarter’s reported figure.
The consensus mark for loss is pegged at 16 cents per share, unchanged over the past 60 days. QSI reported a loss of 16 cents per share in the year-ago quarter.
QSI’s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters, while matching the same on one occasion, with the average surprise being 18.35%.
Let’s see how things have shaped up prior to this announcement.
Quantum-Si Incorporated Price and EPS Surprise
Quantum-Si Incorporated price-eps-surprise | Quantum-Si Incorporated Quote
Key Factors to Note for QSI’s Q2 Earnings
QSI's first-quarter performance is expected to have benefited from rapid traction for its offerings at a global level. At the end of the first quarter of 2025, QSI had 23 international distribution partners, with 60% of instruments installed outside the United States.
QuantumSi is poised for a potential rise in pharma and government adoption of its products. Stability in Pharma and biotech R&D and continuing adoption of the Platinum Pro system are likely to boost QSI’s top line in the second quarter.
QuantumSi is on track to release Version 4 Sequencing Kit and Version 3 of Library Preparation Kit to expand applications, leading to more growth scopes. Proteus platform on track for prototype sequencing in 2025 and commercial launch in H2 2026, promising higher throughput and broader proteomics coverage.
QuantumSi has also been engaging with the scientific community, presenting research at major industry conferences, including the Human Proteome Organization World Congress and the American Society of Human Genetics Conference. QuantumSi’s efforts raise awareness and credibility for its Platinum platform, potentially leading to greater customer adoption.
However, QSI is experiencing a slowdown in new instrument purchases due to NIH funding uncertainty and the U.S. Academic market weakness.
What Our Proven Model Says for QSI’s Q2 Earnings
Our proven model does not conclusively predict an earnings beat for QSI this time. According to the Zacks model, the combination of a positive Earnings ESP and Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here.
QSI has an Earnings ESP of 0.00% and carries a Zacks Rank #3 at present. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks With Favorable Combination
Here are some companies worth considering, as our model shows that these have the right combination of elements to beat earnings in their upcoming releases:
Arista Networks (ANET - Free Report) currently has an Earnings ESP of +0.96% and sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
ANET shares have returned 5.5% in the year-to-date period. It is set to report its second-quarter 2025 results on Aug. 5.
Bumble (BMBL - Free Report) presently has an Earnings ESP of +37.01% and flaunts a Zacks Rank #1.
Bumble shares have lost 6.8% year to date. Bumble is scheduled to report its second-quarter 2025 results on Aug. 6.
Yum! Brands (YUM - Free Report) currently has an Earnings ESP of +1.34% and carries a Zacks Rank #2.
YUM shares have gained 9.4% in the year-to-date period. It is set to report its second-quarter 2025 results on Aug. 5.